GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BriaCell Therapeutics Corp (FRA:8BT0) » Definitions » Book Value per Share

BriaCell Therapeutics (FRA:8BT0) Book Value per Share : €1.69 (As of Apr. 2025)


View and export this data going back to 2015. Start your Free Trial

What is BriaCell Therapeutics Book Value per Share?

BriaCell Therapeutics's book value per share for the quarter that ended in Apr. 2025 was €1.69.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of BriaCell Therapeutics was 64.10% per year. The lowest was -72.30% per year. And the median was -1.30% per year.

BriaCell Therapeutics's current price is €0.607. Its book value per share for the quarter that ended in Apr. 2025 was €1.69. Hence, today's PB Ratio of BriaCell Therapeutics is 0.36.

During the past 13 years, the highest P/B Ratio of BriaCell Therapeutics was 0.42. The lowest was 0.00. And the median was 0.00.


BriaCell Therapeutics Book Value per Share Historical Data

The historical data trend for BriaCell Therapeutics's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BriaCell Therapeutics Book Value per Share Chart

BriaCell Therapeutics Annual Data
Trend Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24
Book Value per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -65.19 23.00 9.81 -3.21 -1.80

BriaCell Therapeutics Quarterly Data
Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.22 -1.80 1.54 1.18 1.69

Competitive Comparison of BriaCell Therapeutics's Book Value per Share

For the Biotechnology subindustry, BriaCell Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BriaCell Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BriaCell Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where BriaCell Therapeutics's PB Ratio falls into.


;
;

BriaCell Therapeutics Book Value per Share Calculation

BriaCell Therapeutics's Book Value Per Share for the fiscal year that ended in Jul. 2024 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-2.20-0.00)/1.22
=-1.80

BriaCell Therapeutics's Book Value Per Share for the quarter that ended in Apr. 2025 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(11.05-0.00)/6.56
=1.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


BriaCell Therapeutics  (FRA:8BT0) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


BriaCell Therapeutics Book Value per Share Related Terms

Thank you for viewing the detailed overview of BriaCell Therapeutics's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


BriaCell Therapeutics Business Description

Traded in Other Exchanges
Address
235-15th Street, Suite 300, 3rd Floor, Bellevue Centre, West Vancouver, Vancouver, BC, CAN, V7T 2X1
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.

BriaCell Therapeutics Headlines

No Headlines